Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Pharma Mar, S.A (0RC6) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Pharma Mar, S.A €11.34, price €70.95, upside -84.0%, quality 86 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
PM
Some data
Oct 3, 2026
Pharma Mar, S.A
0RC6 · LSEQuality Too ExpensiveQuality growthExcellent quality, but the valuation looks stretched.
!Fair value €11.34 · Strongly overvalued (−84.0%)
✓Quality 86/100
!Weak Growth (revenue 5y −3.9 %/yr)
✓Highly profitable · 25.7% net margin (TTM)
✓Low debt · generates free cash flow
!1.4% dividend yield · Watch coverage
!Moderate moat 62/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range €5.84 to €24.20
Watch Pharma Mar, S.A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range €25.26 – €102.24 · fair‑value band €5.84 – €24.20 · the €70.95 price screens above the €11.34 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Company profile
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments.
Show more
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Stock analysis
Pharma Mar, S.A (0RC6) currently trades at €70.95, while our model-based Fair Value estimate is €11.34, 84.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €15.74 per share, and 0 of the 26 models we run sit above the €70.95 price.
Bear case: the Economic Profit group reads lowest at €2.69, and 26 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: €5.84 (bear) to €24.20 (bull), the price of €70.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 86/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Pharma Mar, S.A reported revenue of €221M in FY2025 versus €230M in FY2021, a compound −0.9%/yr. Reported net income was €75.0M in FY2025, compounding −5.2%/yr from FY2021.
Key figures
Market cap €16.4B · P/E ratio 0.1 · P/S ratio 0.05 · EPS (TTM) €5.03 · Dividend yield 1.4% · Net margin 33.9% · Return on equity 24.8% · Return on assets (EBIT) 9.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −84%, 0RC6 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€0.7600 to €16.07). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear €5.84
Fair Value €11.34
Bull €24.20
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€3.05 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV
€1.47
€1.73
€1.96
74
FCF DCF
€3.31
€5.26
€11.47
73
Growth DCF
€3.11
€6.26
€11.42
72
All 26 models by family
DCF Models
FCF DCF
€3.31
€5.26
€11.47
73
Owner Earnings
€5.20
€11.95
€26.12
68
5Y Revenue Exit
€2.18
€3.72
€6.92
67
5Y EBITDA Exit
€2.57
€4.51
€8.30
69
5Y P/E Exit
€5.06
€12.04
€21.64
65
10Y Revenue Exit
€2.48
€5.25
€6.93
64
10Y EBITDA Exit
€2.84
€6.09
€11.67
62
10Y P/E Exit
€4.65
€11.46
€22.89
57
Earnings-Based
Graham-Dodd
€2.30
€16.07
€22.55
61
Lynch FV
€8.30
€11.86
€15.42
59
PEG = 1.0
€8.30
€11.86
€15.42
55
EPV
€1.47
€1.73
€1.96
74
Dividend Discount
Gordon GGM
€0.5800
€1.20
€1.91
64
DDM Multi-Stage
€0.5800
€1.01
€1.26
64
Multiples
P/E Multiple
€5.59
€7.46
€9.32
63
P/S Multiple
€2.63
€3.50
€4.38
58
P/B Multiple
€3.84
€5.12
€6.40
55
EV/EBIT
€2.23
€3.00
€3.78
66
EV/EBITDA
€2.20
€2.97
€3.73
67
EV/Revenue
€1.57
€2.28
€2.99
53
Asset-Based
NCAV (Graham)
€0.5700
€0.7600
€1.14
54
Growth DCF
Growth DCF
€3.11
€6.26
€11.42
72
Rev-Margin DCF
€2.41
€4.27
€8.16
67
Economic Profit
Residual Income
€2.25
€3.60
€9.27
65
ROIC Compounder
€1.87
€2.69
€3.43
69
Growth Earnings
Growth-Adj P/E
€11.02
€15.74
€20.47
65
Notify me when 0RC6 reaches fair value
Put 0RC6 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
86/100
Of which business quality 83 · Market factors (momentum, volatility) 34
Profitability
86
Margins and returns on capital today
Quality Growth
84
Are margins and returns improving?
Cashflow
65
Earnings quality: real cash, not paper profit
Fin. Strength
81
Balance sheet, leverage, solvency risk
Investment
89
Disciplined investing over empire-building
Low Volatility
71
Calm price path (market factor)
Momentum
24
Price trend over the last 3–12 months (market factor)
52W Momentum
11
Distance to the 52-week high (market factor)
Net Issuance
100
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+26.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.9%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−30.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.5%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−7.1% vs 23.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.58% → 18%
2025 sits 193% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes more growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+21.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +8.0% a year for the price and +19.1% for the forecasts.
Forecast 2026 (sales)−1.2%
Forecast 2027 (sales)+34.3%
Projected 2028 (sales)+30.3%
Projected 2029 (sales)+26.2%
Projected 2030 (sales)+22.2%
Compare Pharma Mar, S.A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 626 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Pharma Mar, S.A (0RC6) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of €11.34 versus a price of €70.95, about −84% upside (overvalued).
What is the fair value of 0RC6?
Our model-based fair value for Pharma Mar, S.A is €11.34 (as of Oct 3, 2026), built from audited fundamentals. The current price: €70.95.
What is the quality score of 0RC6?
Pharma Mar, S.A has a Quality Score of 86/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharma Mar, S.A (0RC6)?
Our model-based price target is the fair value of €11.34 (as of Oct 3, 2026) from 26 valuation models. Cautious scenario €5.84, optimistic scenario €24.20. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharma Mar, S.A stock forecast for 2026?
Our models put fair value at €11.34, about −84% upside versus a price of €70.95 (overvalued). Cautious scenario €5.84, optimistic scenario €24.20. The calculation is refreshed regularly with new filings.
What is the revenue of Pharma Mar, S.A (0RC6)?
Pharma Mar, S.A reported trailing-twelve-month revenue of about €219M (latest available figure, as of Oct 3, 2026).
Does Pharma Mar, S.A pay a dividend?
Pharma Mar, S.A currently shows a dividend yield of about 1.41% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Pharma Mar, S.A (0RC6)?
For today's price to be fair in a discounted-cash-flow model, Pharma Mar, S.A would have to grow free cash flow by +10.4 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -3.9 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of 0RC6 use?
Our models discount Pharma Mar, S.A at 8.6 %: a base by market capitalisation (large), damped by beta 0.43, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pharma Mar, S.A that is +10.4 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Pharma Mar, S.A (0RC6) delivered so far?
Over the past 5 years revenue at Pharma Mar, S.A grew -3.9 % a year. The price currently implies +10.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pharma Mar, S.A (0RC6) growing?
The median revenue growth in the sector is +7.1 % a year. That is the yardstick for the growth priced into Pharma Mar, S.A (+10.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pharma Mar, S.A (0RC6)?
The free-cash-flow yield on the price is 3.58 %: that much free cash flow Pharma Mar, S.A produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pharma Mar, S.A (0RC6)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharma Mar, S.A it is €11.34 per share (as of Oct 3, 2026), against a price of €70.95. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Pharma Mar, S.A stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 0RC6 trades above its calculated fair value: price €70.95, fair value €11.34, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RC6?
No. The price is what the market pays today (€70.95); the fair value is what the company's own numbers justify (€11.34). For Pharma Mar, S.A the two are €59.61 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharma Mar, S.A worth?
The market values Pharma Mar, S.A at about €16.4B (market capitalisation, as of Oct 3, 2026). Per share that is €70.95; our models calculate a fair value of €11.34 per share.
What do the bullish and bearish scenarios say about 0RC6?
Our models span a range for Pharma Mar, S.A: cautious scenario €5.84, base €11.34, optimistic €24.20 per share (as of Oct 3, 2026, price €70.95). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0RC6?
Pharma Mar, S.A trades at a price-to-earnings ratio of 0.1 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €11.34 is built from several models across several years.
How solid is the balance sheet of Pharma Mar, S.A (0RC6)?
Balance-sheet figures for Pharma Mar, S.A (as of Oct 3, 2026): return on equity 24.8%, debt of 0.15 per unit of equity. They feed the Quality Score of 86/100, which measures business quality independently of the share price.
How far is 0RC6 from its 52-week high?
Pharma Mar, S.A trades at €70.95, about 31% below its 52-week high of €102.24 and 6% above the low of €66.81 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €11.34 is for.
Which stocks are comparable to Pharma Mar, S.A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharma Mar, S.A stock attractive at the current price?
The data as of Oct 3, 2026: price €70.95, calculated fair value €11.34 (−84%), Quality Score 86/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RC6 calculated?
We run Pharma Mar, S.A through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €11.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Pharma Mar, S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharma Mar, S.A (0RC6)?
The closing price on Oct 2, 2026 was €70.95. Our model-based fair value is €11.34, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharma Mar, S.A right now?
A high-quality business (quality 86/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (€24.20). The favourable scenario is already priced in. The model range is unusually wide (€5.84 to €24.20). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Pharma Mar, S.A
How large is the market capitalisation of Pharma Mar, S.A (0RC6)?
The market capitalisation of Pharma Mar, S.A is €16.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharma Mar, S.A (0RC6)?
The price-to-sales ratio of Pharma Mar, S.A is 0.05 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharma Mar, S.A (0RC6)?
Earnings per share at Pharma Mar, S.A are €5.03 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pharma Mar, S.A (0RC6)?
The dividend yield of Pharma Mar, S.A is 1.4% (payout 19.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharma Mar, S.A (0RC6)?
The net margin of Pharma Mar, S.A is 33.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharma Mar, S.A (0RC6)?
The return on equity (ROE) of Pharma Mar, S.A is 24.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharma Mar, S.A (0RC6)?
On an EBIT basis the return on assets of Pharma Mar, S.A is 9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharma Mar, S.A (0RC6)?
The operating margin of Pharma Mar, S.A is −2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharma Mar, S.A (0RC6)?
Revenue at Pharma Mar, S.A is growing −12.0% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharma Mar, S.A (0RC6)?
Earnings per share at Pharma Mar, S.A are growing +223% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Pharma Mar, S.A (0RC6) carry?
The net debt of Pharma Mar, S.A is €31.6M (fiscal year 2025, ≈ 0.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pharma Mar, S.A in the live analysis
One click puts Pharma Mar, S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.